RxDoctor Payments Data

Ayman Soubra, MD

Urology · Minneapolis, MNNPI 1689053993

Payments from drug & device makers

What this record shows

This record is dominated by grants: $188,811 of the $204,395 with a category attached, or 92.4%. Endo Pharmaceuticals Inc. accounts for 70.2% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2020 at $143,421 and has fallen 98.7% since, to $1,841 in 2025. Among urology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$204,395in general payments, 2019–2025

Across 266 payments — averaging $768.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo Pharmaceuticals Inc.$143K
  • Boston Scientific$54K
  • Coloplast$3K
  • Endo USA, Inc.$847
  • Sumitomo Pharma America, Inc.$439
  • Teleflex LLC$389
  • plus $3K from 36 others

What the payments were for

  • Consulting fees$3,9502%
  • Grants$188,81192%
  • Travel & lodging$3,2232%
  • Food & beverage$8,3344%
  • Education$770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$204,395 in reported general payments places this provider in the 95th percentile of 247 urology providers in Minnesota.

See all urology providers in Minnesota

Medicare billing

Part B allowed, 2024
$281,008
Medicare patients
318
Services billed
7,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron63$40,827
GemtesaVibegron58$37,872
Testosterone39$6,483
Tamsulosin Hcl284$2,791
Testosterone Cypionate30$2,102
Finasteride65$662
Alfuzosin Hcl ErAlfuzosin Hcl34$531
Oxybutynin Chloride ErOxybutynin Chloride19$366
Levofloxacin41$167
Oxycodone Hcl27$121
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim30$119
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$98
Anastrozole13$88
Tramadol Hcl11$19

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$198$40,82763 claims
Sumitomo Pharma America, Inc.Gemtesa$439$37,87258 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 247 urology providers in Minnesota.

Other urology in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →